Key Points
- Major shareholder Gilde Healthcare sold 2,095 Shoulder Innovations shares for $47,347 at an average price of $22.60, retaining approximately 2.21 million shares. Its recent sales totaled more than 110,000 shares and roughly $2.5 million.
- Analyst sentiment remains broadly positive: BTIG and Piper Sandler raised their price targets to $26 and $25, respectively, while UBS initiated coverage with a Buy rating and a $27 target. The stock has a consensus “Moderate Buy” rating and an average target of $23.33.
- Shoulder Innovations continues to show strong revenue growth, but profitability remains weak; the company reported a quarterly loss and analysts expect a full-year loss of $1.67 per share. Shares opened at $20.54 after an 8.4% decline.
Shoulder Innovations, Inc. (NYSE:SI - Get Free Report) major shareholder Healthcare Holding B.V. Gilde sold 2,095 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $22.60, for a total transaction of $47,347.00. Following the completion of the sale, the insider owned 2,212,207 shares of the company's stock, valued at approximately $49,995,878.20. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Healthcare Holding B.V. Gilde also recently made the following trade(s):
- On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.64, for a total transaction of $166,132.32.
- On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.77, for a total transaction of $2,272,719.24.
- On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.71, for a total transaction of $244,155.21.
- On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.73, for a total value of $455,372.82.
- On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The stock was sold at an average price of $23.36, for a total value of $659,803.20.
Shoulder Innovations Trading Down 8.4%
Shares of SI stock opened at $20.54 on Friday. The stock has a market capitalization of $426.06 million and a PE ratio of -10.70. Shoulder Innovations, Inc. has a 1-year low of $10.92 and a 1-year high of $24.59. The business has a 50-day moving average of $19.91 and a 200 day moving average of $16.07. The company has a debt-to-equity ratio of 0.11, a current ratio of 11.81 and a quick ratio of 10.04.
Shoulder Innovations (NYSE:SI - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.03. Shoulder Innovations had a negative return on equity of 22.93% and a negative net margin of 58.33%.The business had revenue of $16.71 million for the quarter. As a group, sell-side analysts anticipate that Shoulder Innovations, Inc. will post -1.67 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on SI. BTIG Research increased their price target on shares of Shoulder Innovations from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Friday. Weiss Ratings upgraded shares of Shoulder Innovations from a "sell (d-)" rating to a "sell (d)" rating in a research report on Monday. UBS Group assumed coverage on shares of Shoulder Innovations in a report on Tuesday, July 28th. They set a "buy" rating and a $27.00 target price for the company. Finally, Piper Sandler reissued an "overweight" rating and issued a $25.00 target price (up from $19.00) on shares of Shoulder Innovations in a research note on Friday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Shoulder Innovations has an average rating of "Moderate Buy" and an average target price of $23.33.
Check Out Our Latest Research Report on SI
Key Shoulder Innovations News
Here are the key news stories impacting Shoulder Innovations this week:
- Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
- Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
- Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
- Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
- Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
- Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale
Hedge Funds Weigh In On Shoulder Innovations
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sectoral Asset Management Inc. lifted its stake in Shoulder Innovations by 14.4% in the fourth quarter. Sectoral Asset Management Inc. now owns 492,435 shares of the company's stock worth $7,042,000 after acquiring an additional 62,153 shares during the period. Deerfield Management Company L.P. purchased a new position in Shoulder Innovations during the 3rd quarter valued at $6,056,000. Alyeska Investment Group L.P. bought a new position in Shoulder Innovations in the 3rd quarter worth $5,667,000. Roubaix Capital LLC lifted its position in shares of Shoulder Innovations by 61.9% in the 1st quarter. Roubaix Capital LLC now owns 257,121 shares of the company's stock worth $3,736,000 after purchasing an additional 98,305 shares during the period. Finally, Vanguard Group Inc. purchased a new stake in shares of Shoulder Innovations in the 3rd quarter worth about $1,836,000.
About Shoulder Innovations
(
Get Free Report)
Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.
In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
